Implantica’s RefluxStop™ gained significant traction at DDW 2025, the world’s premier digestive disease conference, for its breakthrough approach to treating gastroesophageal reflux disease (GERD). Unlike traditional fundoplication procedures, RefluxStop™ employs a non-compressive, non-active implant that restores the natural anatomy without encircling the esophagus, thereby avoiding the common side effects associated with existing surgical solutions. Several independent clinical presentations by leading surgeons showcased the implant’s long-term efficacy and patient satisfaction, drawing attention from gastroenterology experts and healthcare innovators across the U.S.

The device’s importance was underlined by compelling real-world evidence, with studies presented by Dr. med. Zehetner and Dr. Lehmann demonstrating successful outcomes, including in revision surgeries for failed standard treatments. Their findings revealed that RefluxStop™ provided sustained symptom relief and significantly fewer complications, positioning it as a superior option for both primary and secondary GERD interventions. Dr. Reginald Bell, a leading U.S. foregut surgeon and past President of the American Foregut Society, emphasized in his session on procedural innovation that RefluxStop™ represents a major leap in anti-reflux surgery, lauding its potential to reshape patient management in the U.S.

Industry and institutional representatives echoed this sentiment, with Implantica CEO Dr. Peter Forsell praising the efforts of surgeons publishing real-world data and reaffirming the company’s mission to improve GERD care. “RefluxStop™ eliminates many of the undesirable post-operative effects of traditional procedures and offers long-term anatomical preservation,” Forsell said. Surgeons and clinicians attending DDW voiced enthusiastic support for the technology’s U.S. entry, anticipating its FDA approval. As momentum builds, RefluxStop™ is poised to become a cornerstone innovation in global reflux disease treatment, offering a high-impact alternative for millions of patients suffering from chronic GERD.

MedTech Spectrum's Summary

RefluxStop™ introduces a unique non-compressive approach to treating GERD, avoiding common post-surgical complications—sparking strong interest among top U.S. surgeons and global experts during DDW 2025.

European real-world data presented by leading physicians demonstrated the effectiveness of RefluxStop™ both as a primary and revision procedure, showing high patient satisfaction and durable outcomes.

With favorable feedback from the medical community and continued international dialogue, RefluxStop™ is positioned as a disruptive innovation in GERD care, with FDA approval expected to open doors for U.S. market adoption soon.